NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
Cyteir Therapeutics, Inc.
University of Alabama at Birmingham
Vanderbilt-Ingram Cancer Center
Charite University, Berlin, Germany